Equities analysts expect that Proteostasis Therapeutics Inc (NASDAQ:PTI) will post earnings per share (EPS) of ($0.29) for the current quarter, according to Zacks. Zero analysts have made estimates for Proteostasis Therapeutics’ earnings, with estimates ranging from ($0.31) to ($0.26). Proteostasis Therapeutics posted earnings per share of ($0.36) in the same quarter last year, which would suggest a positive year-over-year growth rate of 19.4%. The firm is scheduled to issue its next earnings results on Friday, March 13th.
On average, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($1.20) per share for the current financial year, with EPS estimates ranging from ($1.23) to ($1.18). For the next year, analysts expect that the business will post earnings of ($1.28) per share, with EPS estimates ranging from ($1.61) to ($1.11). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Proteostasis Therapeutics.
Proteostasis Therapeutics (NASDAQ:PTI) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.15.
Several analysts have issued reports on PTI shares. Piper Jaffray Companies restated a “buy” rating and issued a $4.00 price target on shares of Proteostasis Therapeutics in a research report on Tuesday, December 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Proteostasis Therapeutics in a report on Friday, October 18th. Zacks Investment Research raised shares of Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Proteostasis Therapeutics in a report on Monday, December 23rd. Finally, ValuEngine raised shares of Proteostasis Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Five investment analysts have rated the stock with a buy rating, Proteostasis Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $6.75.
In other news, major shareholder Enterprise Associates 12 New sold 117,164 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $2.45, for a total transaction of $287,051.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 19.80% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC lifted its holdings in Proteostasis Therapeutics by 62.4% during the 3rd quarter. Squarepoint Ops LLC now owns 44,569 shares of the company’s stock valued at $38,000 after purchasing an additional 17,120 shares during the last quarter. Paloma Partners Management Co bought a new position in Proteostasis Therapeutics during the 2nd quarter valued at about $150,000. Jane Street Group LLC lifted its holdings in Proteostasis Therapeutics by 445.5% during the 2nd quarter. Jane Street Group LLC now owns 175,050 shares of the company’s stock valued at $171,000 after purchasing an additional 142,958 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new position in Proteostasis Therapeutics during the 2nd quarter valued at about $189,000. 41.49% of the stock is owned by hedge funds and other institutional investors.
NASDAQ PTI traded up $0.03 during midday trading on Friday, hitting $1.96. The company had a trading volume of 1,952,958 shares, compared to its average volume of 6,434,380. The company has a quick ratio of 6.89, a current ratio of 6.89 and a debt-to-equity ratio of 0.18. The stock has a market cap of $98.68 million, a price-to-earnings ratio of -1.53 and a beta of 0.29. The firm has a fifty day simple moving average of $2.52 and a two-hundred day simple moving average of $1.31. Proteostasis Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $4.72.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.
Read More: How is the LIBOR rate calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.